Previous Close | 43.70 |
Open | 43.90 |
Bid | 43.85 x 1800 |
Ask | 43.98 x 800 |
Day's Range | 43.69 - 44.33 |
52 Week Range | 43.33 - 69.10 |
Volume | |
Avg. Volume | 15,909,919 |
Market Cap | 89.172B |
Beta (5Y Monthly) | 0.39 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -3.10 |
Earnings Date | Jul 26, 2024 |
Forward Dividend & Yield | 2.40 (5.49%) |
Ex-Dividend Date | Apr 04, 2024 |
1y Target Est | 49.03 |
Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine are included in this Analyst Blog.
Deciphera Pharmaceuticals, Inc. (DCPH) and GSK are in focus on acquisition news and Q1 earnings, respectively.
Two-year extension for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseasesCAMBRIDGE, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced a two-year extension to the collaboration with Bristol Myers Squibb (NYSE: BMY) under which the parties may research, develop, and commercialize autologous and allogeneic alpha-beta T cell medicines for the treatment of cancer